New data in hand, Regeneron and Sanofi plan to offer insurers new rebates and discounts. Can they end the Mexican standoff that has prevented even the neediest patients from getting a promising drug?
from Forbes Real Time https://www.forbes.com/sites/matthewherper/2018/03/10/sales-flopped-but-does-this-heart-drug-save-lives/
via IFTTT
No comments:
Post a Comment